文献速递急性肾损伤水电解质与酸碱血液净化与透析

局部枸橼酸抗凝与无抗凝在肝衰竭高出血风险患者CKRT中的对比

Regional Citrate Anticoagulation versus No Anticoagulation for CKRT in Patients with Liver Failure with Increased Bleeding Risk.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-11-06

该随机对照试验纳入肝衰竭伴较高出血风险且需CKRT的成人患者,分别接受局部枸橼酸抗凝(44例)或无抗凝CKRT(45例)。无抗凝组滤器失败率显著更高(56% vs 27%,P=0.003),但局部枸橼酸抗凝组低钙血症、严重低钙血症及Ca2+tot/Ca2+ion>2.5发生率显著更高。

要点

  • 无抗凝组滤器失败率显著高于局部枸橼酸抗凝组(56% vs 27%,P=0.003)。
  • 局部枸橼酸抗凝组低钙血症(82% vs 51%,P=0.002)和严重低钙血症(77% vs 13%,P<0.001)发生率更高。
  • 局部枸橼酸抗凝组Ca2+tot/Ca2+ion>2.5发生率为57% vs 7%(P<0.001),多数上调钙替代速率后恢复正常。

核心结论

  • 对于肝衰竭伴较高出血风险且需CKRT的患者,局部枸橼酸抗凝较无抗凝显著延长滤器寿命,但显著增加低钙血症、严重低钙血症及Ca2+tot/Ca2+ion>2.5的风险。

研究设计与样本

  • 随机对照试验,纳入肝衰竭伴较高出血风险且需CKRT的成人患者,局部枸橼酸抗凝组44例,无抗凝组45例。

主要发现

  • 无抗凝组滤器失败率显著高于局部枸橼酸抗凝组(25例[56%] vs 12例[27%],P=0.003),累积 incidence 函数分析和仅纳入首次CKRT会话的敏感性分析证实该结果。
  • 累积 incidence 函数分析中,无抗凝组与局部枸橼酸抗凝组24、48、72小时累积滤器失败率分别为31%、58%、76%与11%、23%、35%。
  • 局部枸橼酸抗凝组Ca2+tot/Ca2+ion>2.5发生率显著高于无抗凝组(57% vs 7%,P<0.001)。
  • 局部枸橼酸抗凝组低钙血症发生率显著高于无抗凝组(82% vs 51%,P=0.002),严重低钙血症发生率亦显著更高(77% vs 13%,P<0.001)。
  • 局部枸橼酸抗凝组中73%的Ca2+tot/Ca2+ion比值升高在上调钙替代速率后恢复正常,且6小时后全身枸橼酸浓度无显著额外升高。

临床怎么用

  • 对于肝衰竭伴较高出血风险且需CKRT的患者,局部枸橼酸抗凝可延长滤器寿命,但需关注低钙血症及Ca2+tot/Ca2+ion>2.5的发生,多数比值升高可通过上调钙替代速率纠正。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The opinions on the efficacy and safety of no anticoagulation versus regional citrate anticoagulation for continuous KRT (CKRT) were controversial in patients with severe liver failure with a higher bleeding risk. We performed a randomized controlled trial to assess no anticoagulation versus regional citrate anticoagulation for CKRT in these patients. METHODS: Adult patients with liver failure with a higher bleeding risk who required CKRT were considered candidates. The included participants were randomized to receive regional citrate anticoagulation or no-anticoagulation CKRT. The primary end point was filter failure. RESULTS: Of the included participants, 44 and 45 were randomized to receive regional citrate anticoagulation and no-anticoagulation CKRT, respectively. The no-anticoagulation group had a significantly higher filter failure rate (25 [56%] versus 12 [27%], P = 0.003), which was confirmed by cumulative incidence function analysis and sensitive analysis including only the first CKRT sessions. In the cumulative incidence function analysis, the cumulative filter failure rates at 24, 48, and 72 hours of the no-anticoagulation and regional citrate anticoagulation groups were 31%, 58%, and 76% and 11%, 23%, and 35%, respectively. Participants in the regional citrate anticoagulation group had significantly higher incidences of Ca 2+tot /Ca 2+ion >2.5 (7% versus 57%, P < 0.001), hypocalcemia (51% versus 82%, P = 0.002), and severe hypocalcemia (13% versus 77%, P < 0.001). However, most (73%) of the increased Ca 2+tot /Ca 2+ion ratios were normalized after the upregulation of the calcium substitution rate. In the regional citrate anticoagulation group, there was no significant additional increase in the systemic citrate concentration after 6 hours. CONCLUSIONS: For patients with liver failure with a higher bleeding risk who required CKRT, regional citrate anticoagulation resulted in significantly longer filter lifespan than no anticoagulation. However, regional citrate anticoagulation in patients with liver failure was associated with a significantly higher risk of hypocalcemia, severe hypocalcemia, and Ca 2+tot /Ca 2+ion >2.5. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: RCA for CRRT in Liver Failure and High Risk Bleeding Patients, NCT03791190 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bai M, Yu Y, Zhao L, et al. Regional Citrate Anticoagulation versus No Anticoagulation for CKRT in Patients with Liver Failure with Increased Bleeding Risk. Clin J Am Soc Nephrol. 2023. PMID: 37990929. doi:10.2215/CJN.0000000000000351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。